In the specialized field of biochemical research, the exploration of protein complexes requires precise tools. As someone who follows advancements in peptide science, I have found that the latency associated peptide antibody is a critical component for researchers investigating the complex regulatory mechanisms of cytokines. Understanding how these tools function helps clarify the complex structural May 19, 2017 — We found that anti-LAP antibody, which targets the latency-associated peptide (LAP)/transforming growth factor-β (TGF-β) complex on Tregs and biology of the transforming growth factor-beta (TGF-β) superfamily.
The Biological Context of Latency Associated Peptide
To appreciate the utility of a specific antibody, one must first look at the target. The latency associated peptide (LAP) is an 80-kDa protein that serves as a fundamental component of the latent TGF-β complex. My review of the literature suggests that TGF-β is synthesized as a large protein precursor and then secreted as a complex of TGF-β and LAP, in which LAP noncov Invitrogen™ LAP (Latency Associated peptide) Monoclonal alently associates with the mature cytokine.
A key detail in this process is that the TGF-β propeptide is covalently bound through disulphide bonds in the endoplasmic reticulum. Furthermore, TGF-beta 1 is expressed as a proprotein that is cleaved within the trans-Golgi to yield the LAP and the mature TGF-beta 1 homodimers. These elements remain associated, forming a "latent" complex because the LAP physically prevents the cytokine from binding to its receptors.
Research Applications and Antibody Specificity
Researchers often utilize various monoclonal antibodies to study these structures. For i Two Distinct Regions of Latency-associated Peptide - PMC nstance, the VB3A9 monoclonal antibody is frequently cited for its ability to recognize human LAP. Similarly, other tools like the TW4-2F8 or TW7-16B4 monoclonal antibodies are used to react with mouse latency associated peptide.
When selecting an antibody for experimental workflows, researchers look for high specificity. Some studies focus on an antibody that specifically bound to the latent form of TGF-β1 presented in the extracellular matrix, effectively preventing its release. The anti-LAP antibody which targets the latency-associated peptide (LAP)/TGF-β complex on Tregs and other cells has become a significant interest for those studying immune regulation in vitro and in vivo.
Structural Insights and Technical Considerations
The str BD Pharmingen™ PE Mouse Anti-Human LAP uctural integrity of these complexes is fascinating. It is well-documented that TGF-β is released from degranulating platelets and secreted from nearly all cells in a bio The peptide you are looking for could not be found. Family of Companies. Brandmark NewBlue. Nordic MUBio Logo. Everest Biotech Logo. logically inactive state. The LAP is a component of the latent complex of TGF-β, which is often disulphide-linked to a protein called LTBP (latent TGF-β binding protein).
For those conducting laboratory assays, it is help by JW Jackson · 2024 · Cited by 21 — Jackson et al. developed an antibody that specifically bound to the latent form of TGF-β1 presented in the extracellular matrix and prevented its release. ful to note:
* Conformational Switching: Structural studies have identified how the peptide switches between bound and unbound states.
* Recombinant Options: Recombinant truncated latency-associated peptide has been utilized in studies to observe impacts on cellular pathways, such as the TGF-β/Smad pathw by SMF Ribeiro · 1999 · Cited by 473 — We now report that the latency-associated peptide (LAP) of the latent TGF-β complex also interacts with thrombospondin-1 as part of a biologically active ay.
* Diversity of Tools: Whether you are looking for a human LAP (TGF-β1) antibody or seeking to understand the latency mechanisms, the availability of validated antibodies is essential for consistent data.
Conclusion
The study of the latency associated peptide and the corresponding peptide research tools continues to evolve. By utilizing specific monoclonal antibodies, scientists can gain deeper insights into how the associated proteins regulate cytokine availability. Whether the focus is on the latency of the complex or the specific associated peptide interactions, these laboratory reagents remain foundational for anyone working with the TGF-β pathway. As research progresses, the ability to isolate and target these specific protein regions will undoubtedly yield further advancements in our understanding of cellular signaling.